{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:45:03Z","timestamp":1782827103782,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,11,18]],"date-time":"2012-11-18T00:00:00Z","timestamp":1353196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s10198-012-0441-4","type":"journal-article","created":{"date-parts":[[2012,11,17]],"date-time":"2012-11-17T16:25:48Z","timestamp":1353169548000},"page":"947-957","source":"Crossref","is-referenced-by-count":12,"title":["Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information"],"prefix":"10.1007","volume":"14","author":[{"given":"Leyla","family":"Mohseninejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talitha","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri\u00ebtte E.","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e8len","family":"Woutersen-Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Buskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,18]]},"reference":[{"key":"441_CR1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1365-2036.2003.t01-1-01736.x","volume":"18","author":"JM Inadomi","year":"2003","unstructured":"Inadomi, J.M., Fennerty, M.B., Bjorkman, D.: Systemic review: the economic impact of irritable bowel syndrome. Aliment. Pharmacol. Ther. 18, 671\u2013682 (2003)","journal-title":"Aliment. Pharmacol. Ther."},{"key":"441_CR2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2036.2003.01456.x","volume":"17","author":"APS Hungin","year":"2003","unstructured":"Hungin, A.P.S., Whorwell, P.J., Tack, J., Mearin, F.: The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Aliment. Pharmacol. Ther. 17, 643\u2013650 (2003)","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"7","key":"441_CR3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/00019053-200220070-00003","volume":"20","author":"RL Akehurst","year":"2002","unstructured":"Akehurst, R.L., Brazier, J.E., Mathers, N., O\u2019Keefe, C., Kaltenthaler, E., Morgan, A.: Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 20(7), 455\u2013462 (2002)","journal-title":"Pharmacoeconomics"},{"key":"441_CR4","unstructured":"ten Berg, M.J., Goettsch, W.G., van den Boom, G., Smout, A.J., Herings, R.M.: Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur. J. Gastroen. Hepat. 18(5), 475\u2013481 (2006)"},{"issue":"4","key":"441_CR5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1524-4733.2007.00179.x","volume":"10","author":"A Bracco","year":"2007","unstructured":"Bracco, A., Jonsson, B., Ricci, J.F., Drummond, M., Nyhlin, H.: Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study. Value Health 10(4), 238\u2013246 (2007)","journal-title":"Value Health"},{"issue":"6","key":"441_CR6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/hec.1074","volume":"15","author":"J Brazier","year":"2006","unstructured":"Brazier, J., Dolan, P., Karampela, K., Towers, I.: Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles. Health Econ. 15(6), 543\u2013551 (2006)","journal-title":"Health Econ."},{"issue":"2","key":"441_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21(2), 271\u2013292 (2002)","journal-title":"J. Health Econ."},{"issue":"11","key":"441_CR8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0895-4356(98)00103-6","volume":"51","author":"J Brazier","year":"1998","unstructured":"Brazier, J., Usherwood, T.: Deriving a preference based single utility index from the UK SF36 health survey. J. Clin. Epidemiol. 51(11), 1115\u20131128 (1998)","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"441_CR9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1524-4733.2006.00086.x","volume":"9","author":"DM Bushnell","year":"2006","unstructured":"Bushnell, D.M., Martin, M.L., Ricci, J.F., Bracco, A.: Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health 9(2), 90\u201397 (2006)","journal-title":"Value Health"},{"issue":"8","key":"441_CR10","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/ajg.2009.232","volume":"104","author":"B Spiegel","year":"2009","unstructured":"Spiegel, B., Harris, L., Lucak, S., Mayer, E., Naliboff, B., Bolus, R., Esrailian, E., Chey, W.D., Lembo, A., Karsan, H., Tillisch, K., Dulai, G., Talley, J., Chang, L.: Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am. J. Gastroenterol. 104(8), 1984\u20131991 (2009)","journal-title":"Am. J. Gastroenterol."},{"key":"441_CR11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1472-6963-10-105","volume":"10","author":"AM Gray","year":"2010","unstructured":"Gray, A.M., Papanicolas, I.N.: Impact of symptoms on quality of life before and after diagnosis of coeliac disease: results from a UK population survey. BMC Health Serv. Res. 10, 105 (2010)","journal-title":"BMC Health Serv. Res."},{"key":"441_CR12","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S0140-6736(01)06581-3","volume":"358","author":"DS Sanders","year":"2001","unstructured":"Sanders, D.S., Carter, J.C., Hurlstone, D.P., Pearce, A., Ward, A.M., McAlindon, M.E., Lobo, A.J.: Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 358, 1504\u20131508 (2001)","journal-title":"Lancet"},{"key":"441_CR13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00042737-200304000-00012","volume":"15","author":"DS Sanders","year":"2003","unstructured":"Sanders, D.S., Patel, D., Stephenson, T.J., Ward, A.M., McCloskey, E.V., Hadjivassiliou, M., Lobo, A.J.: A primary care cross-sectional study of undiagnosed adult coeliac disease. Eur. J. Gastroen. Hepat. 15, 407\u2013413 (2003)","journal-title":"Eur. J. Gastroen. Hepat."},{"key":"441_CR14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2036.2003.01666.x","volume":"15","author":"B Shahbazkhani","year":"2003","unstructured":"Shahbazkhani, B., Forootan, M., Merat, S., Akbari, M.R., Nasserimoghadam, S., Vahedi, H., Malekzadeh, R.: Coeliac disease presenting with symptoms of irritable bowel syndrome. Aliment. Pharmacol. Ther. 15, 231\u2013235 (2003)","journal-title":"Aliment. Pharmacol. Ther."},{"key":"441_CR15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2010.04242.x","volume":"31","author":"T Hershcovici","year":"2010","unstructured":"Hershcovici, T., Leshno, M., Goldin, E., Shamir, R., Israeli, E.: Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet. Aliment. Pharmacol. Ther. 31, 901\u2013910 (2010)","journal-title":"Aliment. Pharmacol. Ther."},{"key":"441_CR16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2036.2004.01958.x","volume":"19","author":"SM Mein","year":"2004","unstructured":"Mein, S.M., Ladabaum, U.: Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis. Aliment. Pharmacol. Ther. 19, 1199\u20131210 (2004)","journal-title":"Aliment. Pharmacol. Ther."},{"key":"441_CR17","unstructured":"Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care (Clinical Practice Guideline). National Institute for Health and Clinical Excellence (2008)"},{"issue":"7","key":"441_CR18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2004.03.012","volume":"126","author":"BM Spiegel","year":"2004","unstructured":"Spiegel, B.M., DeRosa, V.P., Gralnek, I.M., Wang, V., Dulai, G.S.: Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 126(7), 1721\u20131732 (2004)","journal-title":"Gastroenterology"},{"key":"441_CR19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0272989X06289012","volume":"26","author":"R Shamir","year":"2006","unstructured":"Shamir, R., Hernell, O., Leshno, M.: Cost-effectiveness analysis of screening for celiac disease in the adult population. Med. Decis. Making 26, 282\u2013293 (2006)","journal-title":"Med. Decis. Making"},{"key":"441_CR20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2036.2007.03437.x","volume":"26","author":"PPJ Veek van der","year":"2007","unstructured":"van der Veek, P.P.J., van Rood, Y.R., Masclee, A.A.M.: Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome. Aliment. Pharmacol. Ther. 26, 943\u2013952 (2007)","journal-title":"Aliment. Pharmacol. Ther."},{"key":"441_CR21","unstructured":"WGO-OMGE Practice Guideline: Celiac Disease. World Gastroenterology Organisation (WGO-OMGE), Paris (2007)"},{"key":"441_CR22","unstructured":"Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie (Guidelines for pharmacoeconomic research, updated version). College voor zorgverzekeringen (College of Health Insurances, CVZ) (2006)"},{"key":"441_CR23","unstructured":"Richtlijn Coeliakie en Dermatitis Herpetiformis (Coeliac Disease and Dermatitis Herpetiformis Guideline). Nederlandse Vereniging van Maag-Darm-Leverartsen (Dutch Association of Gastroenterologists and Hepatologists) (2008)"},{"key":"441_CR24","unstructured":"van der Linden, M., Westert, G. P., De Bakker, D. H., Schellevis, F. G.: Tweede Nationale studie naar ziekten en verrichtingen in de huisartspraktijk. Klachten en aandoeningen in de bevolking en in de huisartspraktijk (The second Dutch national survey of general practice. Complaints and disorders in the population and in general practice). NIVEL, Utrecht (2004)"},{"key":"441_CR25","doi-asserted-by":"crossref","unstructured":"Damoiseaux, J. G. M. C., Damoiseaux, R. A. M. J.: Coeliakiediagnostiek bij de huisarts (Celiac disease diagnosis in the General practice). Huisarts Wet (General Practitioners & Science) 48(1):24\u201327 (2005)","DOI":"10.1007\/BF03084562"},{"key":"441_CR26","unstructured":"Sanquin Blood Supply Foundation. http:\/\/www.sanquin.nl (1998). Accessed 6 Apr 2010"},{"key":"441_CR27","unstructured":"Nederlandse Zorgautoriteit (Dutch Healthcare Authority). http:\/\/dbc-tarieven.nza.nl\/Nzatarieven\/top.do . Accessed 2 Aug 2010"},{"key":"441_CR28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/pds.997","volume":"13","author":"WG Goettsch","year":"2004","unstructured":"Goettsch, W.G., van den Boom, G., Breekveldt-Postma, N.S., Smout, A.J.P.M., Herings, R.M.C.: Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study. Pharmacol. Drug Saf. 13, 803\u2013810 (2004)","journal-title":"Pharmacol. Drug Saf."},{"key":"441_CR29","unstructured":"Dutch Coeliac Disease organization. http:\/\/www.glutenvrij.nl (2010). Accessed 2 Aug 2010"},{"key":"441_CR30","unstructured":"Statistics Netherlands. www.cbs.nl (2003). Accessed 14 June 2010"},{"key":"441_CR31","unstructured":"Riteco, J. A., de Heij, L., Luijn, J. C. F., Wolff, I. R.: Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie (Guidelines for pharmacoeconomic research, updated version). College voor zorgverzekeringen (College of Health Insurances, CVZ) (1999)"},{"key":"441_CR32","doi-asserted-by":"crossref","unstructured":"Rostami, K., Mulder, C.J., Werre, J.M., van Beukelen, F.R., Kerckhaert, J., Crusius, J.B., Pe\u00f1a, A.S., Willekens, F.L., Meijer, J.W.: High prevalence of celiac disease in apparently healthy blood donors suggests a high prevalence of undiagnosed celiac disease in the Dutch population. Scand. J. Gastroenterol. 34(3):276\u2013279 (1999)","DOI":"10.1080\/00365529950173681"},{"key":"441_CR33","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs, A., Sculpher, M., Claxton, K.: Decision Modelling for Health Economic Evaluation, 1st edn. Oxford University Press, Oxford (2006)","edition":"1"},{"issue":"1","key":"441_CR34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0266462301104058","volume":"17","author":"K Claxton","year":"2001","unstructured":"Claxton, K., Neumann, P.J., Araki, S., Weinstein, M.C.: Bayesian value of information analysis: an application to a policy model of Alzheimer\u2019s disease. Int. J. Technol. Assess. Health Care 17(1), 38\u201355 (2001)","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"3","key":"441_CR35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.163.3.286","volume":"163","author":"A Fasano","year":"2003","unstructured":"Fasano, A., Berti, I., Gerarduzzi, T., Not, T., Colletti, R.B., Drago, S., Elitsur, Y., Green, P.H., Guandalini, S., Hill, I.D., Pietzak, M., Ventura, A., Thorpe, M., Kryszak, D., Fornaroli, F., Wasserman, S.S., Murray, J.A., Horvath, K.: Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch. Intern. Med. 163(3), 286\u2013292 (2003)","journal-title":"Arch. Intern. Med."},{"key":"441_CR36","first-page":"A4584","volume":"156","author":"H Woutersen-Koch","year":"2012","unstructured":"Woutersen-Koch, H., Smout, A.J.P.M., Flik, C.E., Hulshof, C.T.J., de Wit, N.J., van der Horst, H.E.: Multidisciplinaire richtlijn prikkelbaredarmsyndroom (Multidisciplinary guideline for irritable bowel syndrome). Nederlands Tijdschrift voor Geneeskunde (Neth. J. Med.) 156, A4584 (2012)","journal-title":"Nederlands Tijdschrift voor Geneeskunde (Neth. J. Med.)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-012-0441-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-012-0441-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-012-0441-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:01:59Z","timestamp":1714568519000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-012-0441-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,18]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1007\/s10198-012-0441-4","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,18]]}}}